TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17921831
Drug: Spironolactone (12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5-50 mg/day for 3 months)
Study: 15156996
Drug: IN‐BP (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN‐BP (intranasal vaccine without canine‐adenovirus type 2)
Study: 15156996
Drug: IN‐BPA (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN‐BPA (intranasal vaccine with canine‐adenovirus type 2)
Study: 12490862
Drug: OC 3
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC 3 g per day
Study: 12490862
Drug: OC 3
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC 3 g + VD 1 mg per day
Study: 10321142
Drug: Fixed treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed treatments
Study: 10321142
Drug: Functional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatments
Study: 7840077
Drug: Oral-glucose-tolerance test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-glucose-tolerance test (OGTT) on day 14
Study: 7840077
Drug: Oral-sucrose-tolerance test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-sucrose-tolerance test (OSTT) on day 14
Study: 20656
Drug: Benorylate tablets
Normalized name: benorilate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benorylate tablets (4.5 g daily dosage)
Study: 26193987
Drug: Gravity-fed infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gravity-fed infusion (GFI)
Study: 26193987
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump (IP)
Study: 26193987
Drug: Gravity-fed infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gravity-fed infusion with post-administration rinsing (PAR)
Study: 21862934
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of plasmapheresis and immunosuppression
Study: 21862934
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and cytotoxic agents
Study: 21862934
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide
Study: 17320090
Drug: Chokeberry flavonoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry flavonoid extract (3 x 85 mg/day)
Study: 15025841
Drug: Ximelagatran dissolved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran dissolved in water and administered via nasogastric tube
Study: 12575392
Drug: Recombinant roasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant roasted licorice decoction (RRLD) plus low-dose glucocorticoids (GC)
Study: 12575392
Drug: Normal dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dosage of glucocorticoids (GC)
Study: 7874375
Drug: benazepril 5
Normalized name: benazepril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 5 mg + hydrochlorothiazide 6.25 mg
Study: 7874375
Drug: benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg + hydrochlorothiazide 12.5 mg
Study: 3044673
Drug: Hexopal (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexopal (4 g/day)
Study: 21745726
Drug: Anodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex, administered for 20 min at an intensity of 2.0 mA during 150 trials of a probabilistic association learning test.
Study: 24388379
Drug: Ketotifen 0.025%
Normalized name: KETOTIFEN 0.025% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 0.025% ophthalmic solution
Study: 1468429
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg loracarbef in fasting state
Study: 1468429
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg loracarbef following a standard breakfast
Study: 1468429
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg loracarbef with 200 mg acetylcysteine
Study: 6385931
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical indomethacin
Study: 6385931
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical dexamethasone sodium phosphate
Study: 6385931
Drug: Both topical
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both topical indomethacin and dexamethasone
Study: 30074109
Drug: LED-LLLT (830/590
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED-LLLT (830/590 nm) applied after fractional CO2 laser treatment on one side of the face
Study: 24650022
Drug: Ropivacaine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (75 mL, 150 mg)
Study: 17975791
Drug: 14 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Study: 17975791
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Study: 9135733
Drug: Cationic liposomes
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cationic liposomes with plasmid containing human CFTR cDNA (administered to 8 patients)
Study: 3656112
Drug: Benzphetamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzphetamine (25 and 50 mg)
Study: 3656112
Drug: Phenmetrazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenmetrazine (25 and 50 mg)
Study: 3656112
Drug: Mazindol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (0.5, 1.0 and 2.0 mg)
Study: 3656112
Drug: Phenylpropanolamine (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (12.5, 25 and 50 mg)
Study: 31020673
Drug: Susceptibility-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susceptibility-guided therapy (esomeprazole 20 mg, amoxicillin 1 g b.d., clarithromycin 500 mg, metronidazole 400 mg b.d., or levofloxacin 500 mg daily for susceptible infections; bismuth 220 mg b.d. and metronidazole 400 mg q.d.s. for triple-resistant infections)
Study: 31020673
Drug: Empiric therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric therapy (esomeprazole 20 mg, bismuth 220 mg b.d., amoxicillin 1 g, metronidazole 400 mg t.d.s.)
Study: 16595220
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin)
Study: 12671890
Drug: VPA‐985 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA‐985 100 mg/day
Study: 12671890
Drug: VPA‐985 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA‐985 200 mg/day
Study: 11022985
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg daily
Study: 11022985
Drug: Budesonide 1600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 microg daily
Study: 1584644
Drug: Functional orthotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional orthotic therapy (CALIGAMED splint)
Study: 29343449
Drug: 1.5g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5g TXA in 100mL normal saline solution (IA group, n=58)
Study: 29343449
Drug: 1.5g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5g TXA in 100mL normal saline solution (IA group)
Study: 20495498
Drug: Intravascular radiation
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular radiation therapy (IVRT) using Re-188 filled balloon, 18 Gy dose at 0.5 mm depth, after successful coronary angioplasty
Study: 17309153
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) - 4 patients, 4-6 cycles
Study: 17309153
Drug: Chemotherapy/Radiotherapy (CT/RT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/Radiotherapy (CT/RT) - 8 patients, 1-2 cycles of CT before RT and 4 cycles after RT
Study: 17309153
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) - 3 patients, external beam radiotherapy (EBRT), total dose 45 Gy, 24 fractions
Study: 17309153
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival (OS) across all therapy groups
Study: 9180113
Drug: Ticlopidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine plus aspirin
Study: 1336898
Drug: 50-mg doses
Normalized name: docusate sodium 50 MG [Doculase]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg doses of oral etoposide given twice daily for 14 days every 3 weeks
Study: 1336898
Drug: 50-mg doses
Normalized name: docusate sodium 50 MG [Doculase]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg doses of oral etoposide given once daily for 21 days every 4 weeks
Study: 1336898
Drug: 50-mg doses
Normalized name: docusate sodium 50 MG [Doculase]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg doses of oral etoposide given twice daily for 10 days every 3 weeks
Study: 3994433
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg every 6 hours and Tobramycin 1.2 mg/kg every 6 hours (CT)
Study: 26861939
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of antihypertensive medication
Study: 26861939
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of antihypertensive medication
Study: 28925801
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV)
Study: 28925801
Drug: Non-adjuvanted trivalent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted trivalent influenza vaccine (TIV)
Study: 27269416
Drug: Povidone Iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone Iodine (PVI) solution used to cleanse skin around wounds
Study: 15700313
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fenretinide daily for 1 year
Study: 12825106
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (adjustable to 100 or 25 mg)
Study: 1819547
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 0.1 U/kg daily (group A)
Study: 1819547
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 0.1 U/kg daily plus oxandrolone, 0.06 mg/kg (group B)
Study: 6756151
Drug: High-dose estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Study: 6756151
Drug: Medium-dose estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Study: 6756151
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Study: 27213635
Drug: Blended CBT
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended CBT (9 face-to-face sessions, supplemented with digital support via tablet and 3 e-mail contacts)
Study: 27213635
Drug: Regular CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular CBT (12 weekly sessions)
Study: 17639748
Drug: Local periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local periodontal therapy
Study: 15642809
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% timolol treatment for 3 years
Study: 12372573
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (150 mg bolus)
Study: 12372573
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (100 mg bolus)
Study: 9987702
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/d) for 1 day
Study: 9987702
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/d) for 2 weeks
Study: 7582676
Drug: Valine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valine (30 g)
Study: 31640977
Drug: Daptomycin plus
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin plus ceftaroline (combination therapy)
Study: 31640977
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care monotherapy (control)
Study: 25481378
Drug: As-needed budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As-needed budesonide and formoterol therapy
Study: 25481378
Drug: Regular budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Regular budesonide and formoterol therapy
Study: 23675619
Drug: Pulsating electromagnetic
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsating electromagnetic field (PEMF) therapy (15 min exposure, low-frequency PEMF, 5 days/week for 12 weeks)
Study: 21843027
Drug: Gluma Desensitizer
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gluma Desensitizer with G-Cem
Study: 19526754
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) given once a day at a dose of 40 mL after dilution for one week.
Study: 19526754
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical conventional treatment (Control group).
Study: 15476445
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (Genotropin) for six months followed by 12 months of GH for all participants
Study: 1474771
Drug: Intraperitoneal neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal neostigmine (2 mg)
Study: 22877811
Drug: Percutaneous Coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous Coronary Intervention + Optimal Medical Therapy (PCI + OMT)
Study: 20528213
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg suppositories
Study: 20528213
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablets
Study: 16422810
Drug: Vardenafil (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (5-20 mg)
Study: 500834
Drug: Calcium ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium ingestion (0.0, 0.5, 1.5, and 3.0 g of elemental calcium as gluconate)
Study: 31538444
Drug: Decontaminant material
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decontaminant material (sulfonic/sulphuric acid solution, HybenX, EPIEN Medical)
Study: 9929017
Drug: leflunomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide (100 mg daily on days 1-3, then 20 mg daily)
Study: 9929017
Drug: sulphasalazine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphasalazine (0.5 g daily, titrated to 2.0 g daily at week 4)
Study: 7486098
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 mg/mL (0.1%)
Study: 7486098
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg/mL (0.2%)
Study: 7486098
Drug: Ropivacaine 3
Normalized name: fentanyl-ropivacaine 3 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 3 mg/mL (0.3%)
Study: 7486098
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/mL (0.25%)
Study: 11388526
Drug: Ropivacaine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (various doses)
Study: 7486098
Drug: Bupivacaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2.5 mg/mL)
Study: 2354484
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg thrice daily
Study: 466753
Drug: Intravenous 20
Normalized name: Dantrium Intravenous 20mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 20 micrograms NAB 365 (clenbuterol)
Study: 466753
Drug: Intravenous 250
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 250 micrograms terbutaline
Study: 29801515
Drug: DC vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC vaccination as an add-on to the standard therapy
Study: 29801515
Drug: Standard radio/temozolomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radio/temozolomide chemotherapy
Study: 23911183
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy (control)
Study: 15336297
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 20 mg
Study: 21077572
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) 75 mg
Study: 18518892
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg once daily for moderate renal insufficiency; 25 mg once daily for severe renal insufficiency)
Study: 18518892
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by glipizide (2.5 or 5 mg/day, uptitrated to max 20 mg/day)
Study: 11828246
Drug: C (caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (caffeine 4 mg/kg)
Study: 11828246
Drug: E (ephedrine
Normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (ephedrine 0.8 mg/kg)
Study: 11828246
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + E (caffeine 4 mg/kg + ephedrine 0.8 mg/kg)
Study: 11828246
Drug: E (ephedrine
Normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (ephedrine 0.8 mg/kg) and C + E
Study: 8547834
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of retinol (25,000 IU) for 5 years in SKICAP-AK trial
Study: 8547834
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of retinol (25,000 IU) or 13‐cis‐retinoic acid (5 or 10 mg) for 3 years in SKICAP-S/B trial
Study: 2310247
Drug: Nicardipine cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine cardioplegia (0.25 mg/L)
Study: 7003700
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus chemotherapy (RT+CT)
Study: 28109295
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg qd
Study: 28109295
Drug: glimepiride 1-4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 1-4 mg qd
Study: 6366148
Drug: Overall (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (both treatments)
Study: 9332804
Drug: Professional tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional tooth cleaning and oral health education program (test)
Study: 2646206
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg once a day
Study: 8476960
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg day 1 and 100 mg day 2-10
Study: 30683523
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (15mg/kg)
Study: 18317788
Drug: Oral rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifampicin
Study: 18317788
Drug: Submucosal placentrex
Normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submucosal placentrex injection
Study: 15741048
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) - 2 cups containing approximately 250 mg of total catechins
Study: 12512987
Drug: 5% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% carbamide peroxide bleaching gel + potassium nitrate in a custom tray (Colgate Platinum Gentle Plus)
Study: 23272987
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy
Study: 22905891
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg i.v. followed by paracetamol 2 g i.v. 30 min later
Study: 22905891
Drug: Paracetamol 2
Normalized name: Paracetamol 24 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 2 g i.v.
Study: 18367379
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with daily glutamine supplement of 0.35 g/kg
Study: 18367379
Drug: Isocaloric‐isonitrogenous parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric‐isonitrogenous parenteral nutrition (Control)
Study: 12633918
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg buprenorphine tablets sublingually for 10 days